Florida-based wealth advisory J. L. Bainbridge disclosed a purchase of Eli Lilly and Company valued at approximately $45.6 ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.5% in the afternoon session after political comments ...

Since then, supply has returned thanks to Lilly's investments in manufacturing and a move to also offer Zepbound, previously ...

By Stine Jacobsen and Bhanvi Satija COPENHAGEN (Reuters) -Shares of weight-loss drug makers Novo Nordisk and Eli Lilly fell ...

Trump told reporters late Thursday that the list price of Ozempic, which he called “the fat loss drug,” will be “much lower.” ...

South Africa's Aspen Pharmacare said on Monday it had secured regulatory approval to market Eli Lilly's blockbuster diabetes ...

Eli Lilly's blockbuster GLP-1 drugs, Mounjaro and Zepbound, are driving explosive growth as the company prepares to report Q3 ...

According to PharmaTrac data for September 2025, Mounjaro clocked ₹80 crore in monthly sales - just behind GSK’s Augmentin at ...

Eli Lilly's weight-loss drug Mounjaro clocked Rs 80 crore in September sales, a 42% rise month-on-month, becoming India's ...

Shares of Eli Lilly and Novo Nordisk move lower in Thursday's after-hours session after President Trump indicated weight-loss ...

In January, when Sarah le Brocq signed up for a year’s supply of weight loss jab Mounjaro at £99 per month, it felt like a ...

Eli Lilly (NYSE: LLY) is now known for its weight loss drugs. Its stock has risen 150% since mid-2022 because of high demand ...